The transplantation of organs from donors with hepatitis C virus (HCV) infection into uninfected recipients has expanded the available organ donor pool. With the advancement of direct acting antivirals (DAAs), high rates of cure among transplant recipients are possible. Although DAAs are highly effective, treatment failure can occur following an appropriate 12-week course of a pan-genotypic regimen. Here we describe four kidney transplant recipients of organs from donors with HCV infection (three with genotype 3, one genotype 1a) in whom first-line DAA treatment with either glecaprevir-pibrenatasvir or sofosbuvir-velpatasvir was unsuccessful, started 22-35 days after the day of transplantation.